Reaktionsgleichung
[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][CH:9]1[C:13]1[NH:14][C:15]([C:18]2[CH:31]=[CH:30][C:29]3[C:28]4[C:23](=[CH:24][C:25]([C:32]5[NH:33][C:34]([CH:37]6[CH2:41][CH2:40][CH2:39][N:38]6[C:42]([O:44][C:45]([CH3:48])([CH3:47])[CH3:46])=[O:43])=[N:35][CH:36]=5)=[CH:26][CH:27]=4)[CH2:22]C[C:20]=3[CH:19]=2)=[CH:16][N:17]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].CC1(C)C(C)(C)OB(C2C=CC3C4C(=CC(B5OC(C)(C)C(C)(C)O5)=CC=4)C(=O)C=3C=2)[O:51]1>>[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][CH:9]1[C:13]1[NH:14][C:15]([C:18]2[CH:19]=[CH:20][C:29]3[C:28]4[C:23](=[CH:24][C:25]([C:32]5[NH:33][C:34]([CH:37]6[CH2:41][CH2:40][CH2:39][N:38]6[C:42]([O:44][C:45]([CH3:48])([CH3:46])[CH3:47])=[O:43])=[N:35][CH:36]=5)=[CH:26][CH:27]=4)[C:22](=[O:51])[C:30]=3[CH:31]=2)=[CH:16][N:17]=1)=[O:7])([CH3:2])([CH3:4])[CH3:3]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
Followed the procedure used to prepare compound 2-(5-{7-[2-(1-Boc-pyrrolidin-2-yl)-3H-imidazol-4-yl]-9,10-dihydro-phenanthren-2-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester, except that 2,7-bis-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-fluoren-9-one was used instead of 4,4,5,5-tetramethyl-2-[7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-9,10-dihydro-phenanthren-2-yl]-[1,3,2]dioxaborolane. m/z 650.9 (M+H)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-a8d5c0e5920f4aa9b335032f2e931c10
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08841278B2
Verknüpfte Notizen
Wird geladen…